Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease

NCT01872598 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT01872598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01872598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Lead sponsor
AB Science
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
December 31, 2020
Enrollment
721 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease